THE ROLE OF CHECKPOINT INHIBITORS AND CYTOKINES IN ADOPTIVE CELL-BASED CANCER IMMUNOTHERAPY WITH GENETICALLY MODIFIED T-CELLS
This review is focused on the structure and molecular mechanism of chimeric antigen receptor (CAR) efficiency, main aspects of the cell-based product manufacturing technology and clinical application of CAR-T (CAR-modified T lymphocytes) therapy for treatment of hematological and solid tumors. Data referred with an emphasis on the strategies using CAR-T combined with immuno-oncological monoclonal antibodies - checkpoint inhibitors - or various cytokines to boost survival, persistence and anti-tumor efficiency of CAR-T. In addition, the review describes preclinical and clinical data on additive effects of CAR-T therapy combined with monoclonal antibodies targeting immune checkpoints and with a number of interleukins.